An upstream regulator of NRF2, probably inactivates NRF2 in COVID-19, and promotes SARS-CoV-2 entry into the host cell, while activates NRF2 in lung cancer and promotes tumor cell proliferation. This evidence concerns the gene NFE2L2 and lung carcinoma.